CATALAYER NEWS
Novartis’s failed trial for cholesterol drug leads to broad biopharma selloff
Source: MarketWatch Top · 2026-09-08
Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
MORE FROM MARKETWATCH TOP
Trump promises $5,000 checks if Republicans win the midterms. But he also promised tariff and ‘DOGE’ dividends last year
2026-09-10
Diesel prices hit another record high. If you’re shocked, wait until you see your grocery bill.
2026-09-09
Home-insurance premiums just hit a record high. Here’s where they spiked the most.
2026-09-09
Hunter Biden’s memecoin flops, falling 95% just hours after launch
2026-09-09
The bull market’s biggest enemy right now could be Bessent’s interventions
2026-09-09
RELATED ON CATALAYER
Mentioned Tickers
$NVS · NovartisRelated Topics
Biotech & FDA NewsRELATED MARKETS
Prediction Markets